Friends of Cancer Research Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

WASHINGTON--The national cancer community has joined together to create a nonprofit organization, the Friends of Cancer Research, to commemorate the 25th anniversary of the National Cancer Act through a public awareness and education campaign on the importance of cancer research.

WASHINGTON--The national cancer community has joined togetherto create a nonprofit organization, the Friends of Cancer Research,to commemorate the 25th anniversary of the National Cancer Actthrough a public awareness and education campaign on the importanceof cancer research.

The Friends board includes members of the groups most active inthe fight against cancer, including the National Cancer AdvisoryBoard, National Coalition for Cancer Survivorship, Presidents'Cancer Panel, ASCO, AACR, National Alliance of Breast Cancer Organizations,Oncology Nursing Society, National Coalition for Cancer Research,American Cancer Society, and a number of prominent US cancer centers.

The campaign will include events and public forums at which RichardKlausner, MD, director of the National Cancer Institute, and othersenior officials will report to the American people on the stateof cancer research. These events will also provide an opportunityfor the cancer community and other interested parties to identifytheir most important research priorities for the coming years.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
Related Content